Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RSV preventive monoclonal antibody
- Development stage
- Unknown
- Lead developer
- SK bioscience
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intramuscular
01
Overview
RSV preventive monoclonal antibody is a long-acting monoclonal antibody candidate being developed by SK Bioscience and Sanofi for the prevention of respiratory syncytial virus (RSV) infection, primarily in infants. The project is supported by the RIGHT Foundation and the International Vaccine Institute (IVI). This candidate is designed to provide passive immunity by neutralizing the RSV virus, likely through binding to the viral fusion (F) protein, which prevents the virus from fusing with and entering host respiratory cells. Engineered for an extended half-life, the antibody aims to provide protection throughout an entire RSV season with a single dose. It is currently in Phase 1 clinical development.
- Other names
- RSV mAbRSV mAb (preventive)
02
Targets
RSV F (Respiratory syncytial virus fusion protein)
Beyond the preview
Go deeper on RSV preventive monoclonal antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RSV preventive monoclonal antibody.